JP2022507251A5 - - Google Patents

Info

Publication number
JP2022507251A5
JP2022507251A5 JP2021525726A JP2021525726A JP2022507251A5 JP 2022507251 A5 JP2022507251 A5 JP 2022507251A5 JP 2021525726 A JP2021525726 A JP 2021525726A JP 2021525726 A JP2021525726 A JP 2021525726A JP 2022507251 A5 JP2022507251 A5 JP 2022507251A5
Authority
JP
Japan
Prior art keywords
theta
type
methyl
crystalline form
crystal morphology
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021525726A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022507251A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/001199 external-priority patent/WO2020099923A1/en
Publication of JP2022507251A publication Critical patent/JP2022507251A/ja
Publication of JP2022507251A5 publication Critical patent/JP2022507251A5/ja
Priority to JP2024109053A priority Critical patent/JP2024153665A/ja
Pending legal-status Critical Current

Links

JP2021525726A 2018-11-13 2019-11-12 P2x3調節剤としての置換イミダゾピリジン化合物の結晶形態およびそれらの使用 Pending JP2022507251A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024109053A JP2024153665A (ja) 2018-11-13 2024-07-05 P2x3調節剤としての置換イミダゾピリジン化合物の結晶形態およびそれらの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862760307P 2018-11-13 2018-11-13
US62/760,307 2018-11-13
PCT/IB2019/001199 WO2020099923A1 (en) 2018-11-13 2019-11-12 Crystalline forms of a substituted imidazopyridine compound and use thereof as p2x3 modulator

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024109053A Division JP2024153665A (ja) 2018-11-13 2024-07-05 P2x3調節剤としての置換イミダゾピリジン化合物の結晶形態およびそれらの使用

Publications (2)

Publication Number Publication Date
JP2022507251A JP2022507251A (ja) 2022-01-18
JP2022507251A5 true JP2022507251A5 (cg-RX-API-DMAC7.html) 2022-11-16

Family

ID=70732059

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021525726A Pending JP2022507251A (ja) 2018-11-13 2019-11-12 P2x3調節剤としての置換イミダゾピリジン化合物の結晶形態およびそれらの使用
JP2024109053A Pending JP2024153665A (ja) 2018-11-13 2024-07-05 P2x3調節剤としての置換イミダゾピリジン化合物の結晶形態およびそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024109053A Pending JP2024153665A (ja) 2018-11-13 2024-07-05 P2x3調節剤としての置換イミダゾピリジン化合物の結晶形態およびそれらの使用

Country Status (20)

Country Link
US (1) US12637452B2 (cg-RX-API-DMAC7.html)
EP (1) EP3880678B1 (cg-RX-API-DMAC7.html)
JP (2) JP2022507251A (cg-RX-API-DMAC7.html)
CN (1) CN113302191A (cg-RX-API-DMAC7.html)
AU (1) AU2019378161B2 (cg-RX-API-DMAC7.html)
CA (1) CA3119711A1 (cg-RX-API-DMAC7.html)
DK (1) DK3880678T3 (cg-RX-API-DMAC7.html)
ES (1) ES3033466T3 (cg-RX-API-DMAC7.html)
FI (1) FI3880678T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250864T1 (cg-RX-API-DMAC7.html)
HU (1) HUE071480T2 (cg-RX-API-DMAC7.html)
IL (1) IL282996A (cg-RX-API-DMAC7.html)
LT (1) LT3880678T (cg-RX-API-DMAC7.html)
MX (1) MX2021005424A (cg-RX-API-DMAC7.html)
PL (1) PL3880678T3 (cg-RX-API-DMAC7.html)
PT (1) PT3880678T (cg-RX-API-DMAC7.html)
RS (1) RS66922B1 (cg-RX-API-DMAC7.html)
SI (1) SI3880678T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500237T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020099923A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL282087B2 (en) * 2018-10-10 2025-11-01 Bellus Health Cough Inc 4-(imidazo[1,2-a]pyridin-3-yl)-benzamide derivatives for treating pruritus
DK3880678T3 (da) 2018-11-13 2025-06-10 Glaxosmithkline Intellectual Property No 3 Ltd Krystallinske former af p2x3-modulator methyl(s)-2-((2-(2,6-difluoro-4-(methylcarbamoyl )phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholin-4-carboxylat
CA3131312A1 (en) 2019-02-25 2020-09-03 Bellus Health Cough Inc. Treatment with p2x3 modulators
CN114085220B (zh) * 2020-06-22 2023-06-16 上海海雁医药科技有限公司 取代的吗啉-4-羧酸酯衍生物、其组合物及医药上的用途
WO2022001820A1 (zh) * 2020-06-29 2022-01-06 武汉朗来科技发展有限公司 杂环类化合物的晶型及其制备方法和应用
WO2022161462A1 (zh) * 2021-01-29 2022-08-04 上海海雁医药科技有限公司 吗啉衍生物及其药物组合物和用途
AU2024410803A1 (en) * 2023-12-29 2026-07-02 Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. Solid dispersion of p2x3 receptor antagonist and preparation process thereof
WO2025191081A1 (en) 2024-03-15 2025-09-18 Glaxosmithkline Intellectual Property (No.3) Limited Crystalline form of camlipixant
WO2025210540A1 (en) 2024-04-02 2025-10-09 Assia Chemical Industries Ltd. Solid state forms of camlipixant and process for preparation thereof
WO2026022326A1 (en) * 2024-07-25 2026-01-29 Glaxosmithkline Intellectual Property (No.3) Limited P2x3 antagonist formulation
JP2026049185A (ja) 2024-09-06 2026-03-18 キヤノン株式会社 撮像装置、撮像方法、及びコンピュータプログラム
WO2026078642A1 (en) * 2024-10-11 2026-04-16 Apitoria Pharma Private Limited Novel crystalline form of camlipixant and process for the preparation thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH503559A (de) 1969-02-26 1971-02-28 Arx Paul Von Vorrichtung an Tafelschere zum Schneiden nach Markierungen, unter ständiger Beobachtung des Schnittes
GB9119920D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EE05345B1 (et) 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
BR0111230A (pt) 2000-05-31 2003-06-10 Astrazeneca Ab Composto, e, uso e processo para a preparação do mesmo
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
KR20030014425A (ko) 2000-07-07 2003-02-17 앤지오젠 파마슈티칼스 리미티드 혈관 손상제인 콜치놀 유도체
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
AU2002305236A1 (en) 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kits for treatment of respiratory and lung disease with anti-sense oligonucleotides and a bronchodilating agent
WO2003014732A1 (en) * 2001-08-10 2003-02-20 Symyx Technologies, Inc. Apparatuses and methods for creating and testing pre-formulations and systems for same
SE0102808D0 (sv) 2001-08-22 2001-08-22 Astrazeneca Ab New compounds
JP2004002826A (ja) 2002-04-24 2004-01-08 Sankyo Co Ltd 高分子イミダゾピリジン誘導体
BRPI0515897A (pt) 2004-09-24 2008-08-12 Astrazeneca Ab composto, uso do mesmo, composição farmacêutica, e, método para a terapia de dor em um animal de sangue quente, e para a preparação de um composto
JP5198256B2 (ja) 2005-05-04 2013-05-15 エボテク エージー 縮合複素環式化合物、並びにそれらの組成物及び使用
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
US20090099195A1 (en) 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
US20110237578A1 (en) 2008-09-18 2011-09-29 Zhi-Liang Wei Amide compounds, compositions and uses thereof
ES2442797T3 (es) 2009-11-18 2014-02-13 Neomed Institute Compuestos de benzoimidazol y sus utilizaciones
WO2013002584A2 (ko) 2011-06-28 2013-01-03 주식회사 비보존 다중 타겟팅의 상승 효과를 유발하는 유효물질의 조합 및 그 용도
KR102120513B1 (ko) 2013-01-31 2020-06-08 네오메드 인스티튜트 이미다조피리딘 화합물 및 이의 용도
BR112016003157B1 (pt) 2013-08-15 2021-07-13 Volvo Truck Corporation Método e disposição para balanceamento de um sistema de armazenamento de energia
PE20160431A1 (es) 2013-08-23 2016-06-02 Afferent Pharmaceuticals Inc Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o cronica
CU24411B1 (es) 2014-12-09 2019-05-03 Bayer Ag Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
CA2998742C (en) 2015-09-29 2023-08-29 Anthony P. FORD Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough
US9907795B2 (en) 2016-01-08 2018-03-06 Nerre Therapeutics Limited Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents
US10822311B2 (en) 2016-03-14 2020-11-03 Afferent Pharmaceuticals, Inc. Pyrimidines and variants thereof, and uses therefor
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
CN109996546B (zh) 2016-09-30 2023-06-27 阿沙纳生物科学公司 P2x3和/或p2x2/3化合物及方法
US10111883B1 (en) * 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
IL282087B2 (en) 2018-10-10 2025-11-01 Bellus Health Cough Inc 4-(imidazo[1,2-a]pyridin-3-yl)-benzamide derivatives for treating pruritus
DK3880678T3 (da) 2018-11-13 2025-06-10 Glaxosmithkline Intellectual Property No 3 Ltd Krystallinske former af p2x3-modulator methyl(s)-2-((2-(2,6-difluoro-4-(methylcarbamoyl )phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholin-4-carboxylat
WO2020112890A1 (en) 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Rnaset2 compositions and methods of treatment therewith
KR102797127B1 (ko) 2018-12-29 2025-04-21 우한 크리에이터나 사이언스 앤드 테크놀로지 컴퍼니, 리미티드 헤테로고리계 화합물, 중간체, 이의 제조 방법 및 용도
CA3131312A1 (en) 2019-02-25 2020-09-03 Bellus Health Cough Inc. Treatment with p2x3 modulators
JP2023513373A (ja) 2020-02-14 2023-03-30 べルス・ヘルス・コフ・インコーポレーテッド P2x3修飾薬
BR112022015818A2 (pt) 2020-02-14 2022-10-25 Bellus Health Cough Inc Preparação de um antagonista de p2x3

Similar Documents

Publication Publication Date Title
FI3880678T3 (fi) P2x3-muuntaja metyyli-(s)-2-((2-(2,6-difluori-4-(metyylikarbamoyyli)fenyyli)-7-metyyli-imidatso[1,2-a]pyridin-3-yyli)metyyli)morfoliini-4-karboksylaatin kidemuotoja
JP2022511800A5 (cg-RX-API-DMAC7.html)
US10035802B2 (en) Solid state forms of ibrutinib
JP2025176008A5 (cg-RX-API-DMAC7.html)
JP2023116503A5 (cg-RX-API-DMAC7.html)
JP2017526711A5 (cg-RX-API-DMAC7.html)
JP2009520690A5 (cg-RX-API-DMAC7.html)
JP2025511847A5 (cg-RX-API-DMAC7.html)
JP2024526882A5 (cg-RX-API-DMAC7.html)
JP2024534014A5 (cg-RX-API-DMAC7.html)
JP2010514807A5 (cg-RX-API-DMAC7.html)
CN110139860A (zh) 1,3,5-三嗪衍生物的盐及其晶体、它们的制备方法、药物组合物和用途
JP2007532560A5 (cg-RX-API-DMAC7.html)
JP2024521412A5 (cg-RX-API-DMAC7.html)
JP2025143254A5 (cg-RX-API-DMAC7.html)
JP2024518429A5 (cg-RX-API-DMAC7.html)
JP2025131661A (ja) 2-(5-(4-(2-モルホリノエトキシ)フェニル)ピリジン-2-イル)-n-ベンジルアセトアミドの固体形態
KR20180018551A (ko) 아파티닙 유리 염기 및 아파티닙 디말레에이트의 다형체 형태
JP2023524518A5 (cg-RX-API-DMAC7.html)
US20140303185A1 (en) Novel polymorphs of vilazodone hydrochloride
US11286247B2 (en) Acryloyl-containing nuclear transport regulators and uses thereof
JP2023521411A5 (cg-RX-API-DMAC7.html)
JP2006513185A5 (cg-RX-API-DMAC7.html)
JP2024542840A5 (cg-RX-API-DMAC7.html)
HRP20180865T1 (hr) Kristalni oblik abakavira koji uglavnom ne sadrži otapalo